compound semaglutide shortage FDA ends shortage, closing the door on compounded Wegovy, Ozempic Some doctors are embracing compounded

This trial, ATTAIN-2, was a double-blind 72-week trial in 136 sites across 10 countries

GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have produced some of the most dramatic weight loss outcomes in the history of pharmacology

In the SURPASS-2 study, the three doses of tirzepatide (5, 10, and 15 mg once weekly) were tested with the GLP-1RA semaglutide (1 mg once weekly) as a comparator in patients not optimally controlled on monotherapy with metformin (71)

There is no official clinical guidance supporting this combination, and any perceived benefits reported anecdotally online should be interpreted with significant scepticism